NASDAQ · Key Statistics

Ironwood Pharmaceuticals, Inc. (IRWD) P/E Ratio, ROE & Key Statistics

$4.87 NASDAQ: IRWD Market Cap $806.23M

Data as of Nov 17, 2026 close · Source: Financial Modeling Prep (methodology)

Every valuation, profitability, balance-sheet and per-share figure DeltaScreener holds for Ironwood Pharmaceuticals, Inc. (IRWD), each with what it measures. Figures are trailing twelve months or the most recent reported period.

Valuation

MetricValue
P/E ratioShare price divided by earnings per share.5.36
P/B ratioShare price divided by book value per share.0.00
P/S ratioMarket value divided by annual revenue.2.01
PEG ratioP/E divided by the earnings growth rate.0.01
EV / EBITDAEnterprise value against earnings before interest, tax, depreciation and amortisation.2.82
EV / RevenueEnterprise value against annual revenue.1.82
Earnings yieldEarnings per share as a percentage of the share price — the inverse of P/E.18.66%
Free cash flow yieldFree cash flow as a percentage of market value.25.54%
Price / free cash flowMarket value divided by free cash flow.6.34

Profitability

MetricValue
Gross marginRevenue left after the direct cost of goods sold.99.89%
Operating marginRevenue left after operating costs.62.84%
Net marginRevenue left after every cost, including tax and interest.37.38%
Return on equityProfit as a percentage of shareholders’ equity.-93.40%
Return on assetsProfit as a percentage of total assets.51.49%
Return on capital employedOperating profit against the capital the business uses.98.31%

Financial health

MetricValue
Current ratioCurrent assets divided by current liabilities. Above 1 means short-term assets cover short-term bills.6.51
Quick ratioThe same, excluding inventory.6.51
Cash ratioCash alone against current liabilities.0.89
Debt to equityTotal borrowings against shareholders’ equity.-2.28
Debt to assetsTotal borrowings against total assets.1.51
Interest coverageHow many times operating profit covers the interest bill.8.27

Per share and size

MetricValue
Earnings per shareProfit attributable to each share.$0.91
Book value per shareShareholders’ equity divided by shares outstanding.−$0.59
Market capitalisationShare price times shares outstanding.$806.23M
Enterprise valueMarket value plus net debt — what it would cost to buy the business outright.$1.12B
EmployeesReported headcount.253

Dividend

MetricValue
Dividend yieldAnnual dividend as a percentage of the share price.0.00%

Ironwood Pharmaceuticals, Inc. (IRWD) statistics — frequently asked questions

What is Ironwood Pharmaceuticals, Inc.'s P/E ratio?

Ironwood Pharmaceuticals, Inc. (IRWD) trades on a price-to-earnings ratio of 5.36.

What is Ironwood Pharmaceuticals, Inc.'s return on equity?

Ironwood Pharmaceuticals, Inc. (IRWD) reports a return on equity of -93.40%, meaning it generated that much profit for every dollar of shareholders' equity.

How much debt does Ironwood Pharmaceuticals, Inc. carry?

Ironwood Pharmaceuticals, Inc. (IRWD) has a debt-to-equity ratio of -2.28, which compares total borrowings with shareholders' equity.

What is Ironwood Pharmaceuticals, Inc.'s profit margin?

Ironwood Pharmaceuticals, Inc. (IRWD) keeps 37.38% of revenue as net profit after every cost, including tax and interest.

P/E and ROE of other Drug Manufacturers - Specialty & Generic stocks

TEVA P/E 94.73ZTS P/E 13.82VTRS ROE -4.24%ELAN ROE -2.24%RDY P/E 39.94ALKS key statisticsAMRX P/E 50.49LNTH P/E 24.54SUPN ROE -4.14%BHC key statisticsAll Drug Manufacturers - Specialty & Generic stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.